Eli Lilly cut its outlook for fourth-quarter revenue citing sluggish growth in the market for incretin, which increases insulin levels.
Related Posts
Volkswagen to Invest Up to $5 Billion Into EV Maker Rivian
Rivian shares rise in aftermarket trading as the automakers plan creation of a joint venture to work on vehicle software.
BHP’s Iron Ore, Copper Production Rises
Mining giant BHP Group said it produced more iron ore and copper over the past year thanks to new and acquired mines in Australia, but […]
Apple Sales Hit Quarterly Record as iPhone Business Rebounds
Apple reported record revenue for the September quarter, propelled by a modest rebound in iPhone sales that came ahead of its release of new AI […]